공시 • May 06
IMCD N.V. to Report Q1, 2027 Results on Apr 29, 2027 IMCD N.V. announced that they will report Q1, 2027 results on Apr 29, 2027 공시 • May 03
IMCD N.V. Approves Cash Dividend, Payable on 8 May 2026 IMCD N.V., at the AGM held on April 30, 2026 approved cash dividend of EUR 1.81 per share. Ex-dividend date is 5 May 2026. Dividend record date is 6 May 2026. Dividend payment date is 8 May 2026. 공시 • Feb 21
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Willows Ingredients Group Limited. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Willows Ingredients Group Limited on February 20, 2026. Through the integration of Willows Ingredients’ supplier partnerships, IMCD will broaden its portfolio and market access to customers throughout Ireland and the UK.
The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2026. 공시 • Feb 18
IMCD N.V. Proposes Dividend for the Year 2025 IMCD N.V. proposed dividend of EUR 1.81 in cash per share (2024: EUR 2.15) for the year 2025. 공시 • Dec 13
IMCD N.V. Announces Chief Financial Officer Changes IMCD N.V. announced that its Supervisory Board nominates Floris Lagerwerf to become Chief Financial Officer (CFO) of IMCD as of January 2027. Floris will succeed Hans Kooijmans, who has decided to retire as per the end of December 2026. Floris started his career as external auditor in 2006, and he joined IMCD in its Rotterdam headquarters in 2016 as Group Controller. In 2021 he became Finance & Operations Director at IMCD Switzerland, and since January 2023, serves as Vice-President Finance & Operations for the Americas region. As of January 1, 2026, Floris will be Vice-President Finance & Operations EMEA and Industrial Business Groups. Hans Kooijmans will remain CFO of IMCD until the end of 2026 and will support Floris towards the transition in 2027. 공시 • Oct 17
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Dong Yang FT Corp. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Dong Yang FT Corp. on October 16, 2025. For the period ending December 31, 2024, Dong Yang FT Corp. reported total revenue of KRW 55.3 billion. The transaction is subject to customary (regulatory) closing conditions and is expected to close in the first quarter of 2026. 공시 • Aug 27
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Tillmanns Spa. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Tillmanns Spa on August 27, 2025.
In 2024, Tillmanns reported annual revenues of ca. €143 million.
The transaction is subject to customary (regulatory) closing conditions and is expected to close in the fourth quarter of 2025.
Domenico Colella and Pietro Masi of Orsingher Ortu Avvocati Associati acted as legal advisor for IMCD N.V. (ENXTAM:IMCD). Ethica Holding S.p.A. acted as financial advisor for the shareholders of Tillmanns Spa. Massimo Di Terlizzi, Graziana Toscano, Giorgio Recine, and Costanza Ceruti of Studio Pirola Pennuto Zei & Associati acted as legal advisor for the shareholders of Tillmanns Spa. For strategic and tax matters, Tillmanns and its partner were supported by Stefano Cesati of Studio Pirola Pennuto Zei & Associati. 공시 • Jul 31
IMCD N.V., Annual General Meeting, Apr 30, 2026 IMCD N.V., Annual General Meeting, Apr 30, 2026. 공시 • Jun 30
IMCD N.V. (ENXTAM:IMCD) agreed to acquire Apus Química SpA. IMCD N.V. (ENXTAM:IMCD) agreed to acquire Apus Química SpA on June 30, 2025. The terms of the transaction are undisclosed.
For the period ending December 31, 2024, Apus Química SpA reported total revenue of approximately €15 million.
The transaction is subject to customary closing conditions and is expected to close in July 2025. 공시 • Jun 06
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Ferrer Alimentacion Sa. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Ferrer Alimentacion Sa on June 6, 2025.
For the period ending December 31, 2024, Ferrer Alimentacion Sa reported total revenue of €112 million.
The transaction is subject to customary closing conditions and is expected to close in June 2025. 공시 • Mar 06
IMCD N.V. announces Annual dividend, payable on May 06, 2025 IMCD N.V. announced Annual dividend of EUR 2.1500 per share payable on May 06, 2025, ex-date on April 29, 2025 and record date on April 30, 2025. 공시 • Nov 14
IMCD N.V. has filed a Follow-on Equity Offering in the amount of €300 million. IMCD N.V. has filed a Follow-on Equity Offering in the amount of €300 million.
Security Name: Ordinary Shares
Security Type: Common Stock Buy Or Sell Opportunity • Nov 05
Now 20% undervalued Over the last 90 days, the stock has risen 5.8% to €143. The fair value is estimated to be €180, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 5.0% per annum. Earnings are also forecast to grow by 8.7% per annum over the same time period. 공시 • Oct 17
IMCD N.V. (ENXTAM:IMCD) agreed to acquire Blumos Group. IMCD N.V. (ENXTAM:IMCD) has signed an agreement to acquire Blumos Group on October 17, 2024.
The transaction is subject to customary regulatory closing conditions. The expected completion of the transaction is in the fourth quarter of 2024. Buy Or Sell Opportunity • Aug 09
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.3% to €138. The fair value is estimated to be €174, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 8.3% per annum over the same time period. Reported Earnings • Aug 04
First half 2024 earnings released: EPS: €2.48 (vs €2.68 in 1H 2023) First half 2024 results: EPS: €2.48 (down from €2.68 in 1H 2023). Revenue: €2.39b (up 4.2% from 1H 2023). Net income: €141.3m (down 7.5% from 1H 2023). Profit margin: 5.9% (down from 6.6% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. 공시 • Aug 03
IMCD N.V., Annual General Meeting, Apr 25, 2025 IMCD N.V., Annual General Meeting, Apr 25, 2025. Buy Or Sell Opportunity • Jul 09
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 16% to €129. The fair value is estimated to be €161, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 5.7% per annum. Earnings are also forecast to grow by 6.8% per annum over the same time period. 공시 • May 16
IMCD N.V. Approves Dividend for the Year 2023, Payable on 21 May 2024 IMCD N.V. announced that at its AGM held on May 14, 2024, approved the dividend proposal of EUR 2.24 per share in cash. Ex-dividend date is on 16 May 2024. Dividend record date is on 17 May 2024. Dividend payment date is on 21 May 2024. Upcoming Dividend • May 09
Upcoming dividend of €2.24 per share Eligible shareholders must have bought the stock before 16 May 2024. Payment date: 21 May 2024. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.1%). Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €158, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 15x in the Trade Distributors industry in Europe. Total returns to shareholders of 46% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €153 per share. Reported Earnings • Mar 04
Full year 2023 earnings released: EPS: €5.14 (vs €5.50 in FY 2022) Full year 2023 results: EPS: €5.14 (down from €5.50 in FY 2022). Revenue: €4.46b (down 3.4% from FY 2022). Net income: €292.3m (down 6.6% from FY 2022). Profit margin: 6.5% (down from 6.8% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Mar 01
Now 20% overvalued Over the last 90 days, the stock has fallen 2.2% to €138. The fair value is estimated to be €115, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 35%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings are also forecast to grow by 4.2% per annum over the same time period. New Risk • Feb 28
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €693k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (76% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Significant insider selling over the past 3 months (€693k sold). Buy Or Sell Opportunity • Jan 21
Now 20% undervalued Over the last 90 days, the stock has risen 28% to €141. The fair value is estimated to be €178, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 35%. Revenue is forecast to grow by 8.0% in 2 years. Earnings are forecast to grow by 6.5% in the next 2 years. Buying Opportunity • Jan 18
Now 21% undervalued Over the last 90 days, the stock is up 29%. The fair value is estimated to be €181, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 35%. Revenue is forecast to grow by 8.0% in 2 years. Earnings is forecast to grow by 6.5% in the next 2 years. 공시 • Jan 10
IMCD N.V. (ENXTAM:IMCD) acquired 70% stake in Valuetree Ingredients Private Limited from the founders of Valuetree Ingredients Private Limited. IMCD N.V. (ENXTAM:IMCD) acquired 70% stake in Valuetree Ingredients Private Limited from the founders of Valuetree Ingredients Private Limited on January 10, 2024. IMCD N.V. (ENXTAM:IMCD) will acquire the remaining 30% stake in Valuetree Ingredients Private Limited in 2025. The founders of Valuetree will continue to lead the company post-completion of this first tranche. For the financial year ended on March 31, 2023 Valuetree Ingredients Private Limited generated revenue of approximately INR 4.4 billion. IMCD N.V. (ENXTAM:IMCD) completed the acquisition of 70% stake in Valuetree Ingredients Private Limited from the founders of Valuetree Ingredients Private Limited on January 10, 2024. 공시 • Nov 30
IMCD Appoints Dorthe Mikkelsen as Member of the Supervisory Board IMCD N.V. announced that Mrs. Dorthe Mikkelsen has been appointed as member of the Supervisory Board at the Extraordinary General Meeting of IMCD N.V. held on 27 November 2023. Buying Opportunity • Aug 14
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 9.1%. The fair value is estimated to be €162, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 35%. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings is also forecast to grow by 7.2% per annum over the same time period. Reported Earnings • Aug 06
First half 2023 earnings released: EPS: €2.68 (vs €3.11 in 1H 2022) First half 2023 results: EPS: €2.68 (down from €3.11 in 1H 2022). Revenue: €2.30b (down 1.3% from 1H 2022). Net income: €152.7m (down 14% from 1H 2022). Profit margin: 6.6% (down from 7.6% in 1H 2022). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. 공시 • Aug 02
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Sachs Chemical, Inc. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Sachs Chemical, Inc. on August 1, 2023. Sachs Chemical, Inc. generated a revenue of approximately $50 million in 2022. IMCD welcomes Sachs’ 38 employees to its local organization. The closing of the transaction is subject to customary closing conditions and is expected to take place in August 2023. 공시 • Jun 17
IMCD N.V. (ENXTAM:IMCD) agreed to acquire Brylchem Group. IMCD N.V. (ENXTAM:IMCD) agreed to acquire Brylchem Group on June 16, 2023. IMCD will acquire Brylchem Pte Ltd, Chemipac Pte Ltd, and CMS Marketing Trading Co., Ltd. Brylchem Group achieved a revenue of approximately SGD 85 million in 2022. The transaction is expected to be completed in the fourth quarter of 2023, subject to customary closing conditions. 공시 • May 19
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Euro Chemo-Pharma Sdn. Bhd. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Euro Chemo-Pharma Sdn. Bhd. on May 19, 2023. In this transaction, IMCD will also acquire Euro Chemo-Pharma's wholly owned subsidiary, Biofresh Green Sdn Bhd. Euro Chemo-Pharma has reported revenue of approximately MYR 270 million during financial year ended on June 30, 2022. The closing of the transaction is subject to customary closing conditions. The transaction is expected to take place in the last quarter of 2023. 공시 • May 06
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Koi Products Solutions & Engineering Ltd. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Koi Products Solutions & Engineering Ltd on May 5, 2023. KOI Products has generated a revenue of above €8 million in financial year 2022 and adds 13 employees to the IMCD Israel team. The closing of the transaction is subject to customary closing conditions and is expected to take place in June 2023. Upcoming Dividend • Apr 21
Upcoming dividend of €2.37 per share at 1.6% yield Eligible shareholders must have bought the stock before 28 April 2023. Payment date: 04 May 2023. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (2.7%). Reported Earnings • Feb 27
Full year 2022 earnings released: EPS: €5.50 (vs €3.64 in FY 2021) Full year 2022 results: EPS: €5.50 (up from €3.64 in FY 2021). Revenue: €4.62b (up 34% from FY 2021). Net income: €313.1m (up 51% from FY 2021). Profit margin: 6.8% (up from 6.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. 공시 • Feb 17
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire CPS Chemical Oil-Tech (Pty) Ltd. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire CPS Chemical Oil-Tech (Pty) Ltd on February 16, 2023. CPS Oil-Tech generated a revenue of approximately ZAR 228 million in the financial year that ended on February 28, 2022. The company represents leading global suppliers and serves a large group of customers with an extensive portfolio of products alongside commercial and technical support. Joining forces with CPS Oil-Tech will enable IMCD South Africa to offer its customers an increased product offering, through the valued strategic principals that CPS Oil-Tech, already represents. The closing of the transaction is subject to customary closing conditions and regulatory approval and is expected to take place in the second quarter of 2023. 공시 • Nov 23
IMCD N.V. (ENXTAM:IMCD) entered into an agreement to acquire Parkash DyeChem Private Limited. IMCD N.V. (ENXTAM:IMCD) entered into an agreement to acquire Parkash DyeChem Private Limited on November 21, 2022. The closing of the transaction is subject to customary closing conditions and is expected to take place in December 2022. 공시 • Oct 11
IMCD N.V. to Report First Half, 2023 Results on Aug 04, 2023 IMCD N.V. announced that they will report first half, 2023 results on Aug 04, 2023 공시 • Sep 08
IMCD N.V. (ENXTAM:IMCD) acquired 100% of the shares in Kuni Chemical Co., Ltd. IMCD N.V. (ENXTAM:IMCD) acquired 100% of the shares in Kuni Chemical Co., Ltd. on September 7, 2022. Kuni Chemical generated a revenue of approximately JPY 2,500 million in 2021 and has 28 employees.IMCD N.V. (ENXTAM:IMCD) completed the acquisition of 100% of the shares in Kuni Chemical Co., Ltd. on September 7, 2022 Buying Opportunity • Sep 02
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 3.9%. The fair value is estimated to be €175, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 31%. For the next 3 years, revenue is forecast to grow by 4.7% per annum. Earnings is also forecast to grow by 6.1% per annum over the same time period. Reported Earnings • Aug 05
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down €105.4m from profit in 1H 2021). Profit margin: (down from 6.2% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 3.3%, compared to a 10% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 26% per year. 공시 • Jun 22
IMCD N.V. (ENXTAM:IMCD) has signed an agreement to acquire Welex S.A. Holdings (China) Limited. IMCD N.V. (ENXTAM:IMCD) has signed an agreement to acquire Welex S.A. Holdings (China) Limited on June 21, 2022. Welex generated a revenue of approximately HKD 322 million in 2021 and has 68 employees. The closing of the transaction is expected to take place at the earliest of 31 October 2022. 공시 • May 03
IMCD N.V. Appoints Marcus Jordan as Chief Operating Office and New Member of the Management Board IMCD N.V. announces the appointment of Marcus Jordan was appointed as Chief Operating Officer and new member of the Management Board for a first term of four years. Marcus Jordan currently serves as President of Americas and throughout his 23-year career with IMCD, has led various strategic roles in the UK as well as in the Group organization, amongst which the role of Group Development Director. The responsibilities of Mr. Jordan as COO include the Group’s strategy execution for digitization and sustainability and driving operational excellence globally. 공시 • May 02
IMCD Stops Its Business in Russia The Management Board of IMCD N.V. has decided to discontinue business in Russia and close its offices in St. Petersburg and Moscow. This follows IMCD’s decision of early March to suspend import and export operations in Russia and scale down the local business due to increasing international sanctions. IMCD will wind down its operations and continue to support the employees in its Russian offices throughout the transition process. Upon completion, IMCD will no longer have a presence in Russia. The discontinuation of activities in Russia has no material impact on IMCD’s results for 2022. Upcoming Dividend • Apr 27
Upcoming dividend of €1.62 per share Eligible shareholders must have bought the stock before 04 May 2022. Payment date: 09 May 2022. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (4.0%). Lower than average of industry peers (2.5%). 공시 • Feb 18
IMCD N.V. (ENXTAM:IMCD) agreed to acquire Quelaris Internacional S.A. IMCD N.V. (ENXTAM:IMCD) agreed to acquire Quelaris Internacional S.A. on February 17, 2022. Quelaris has Generated a revenue of approximately $52 million in 2021. The closing of the transaction is expected to take place in March 2022. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €163, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 18x in the Trade Distributors industry in Europe. Total returns to shareholders of 188% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €96.84 per share. 공시 • Dec 23
IMCD N.V. (ENXTAM:IMCD) agreed to acquire Polychem Handelsgesellschaft M.B.H. IMCD N.V. (ENXTAM:IMCD) agreed to acquire Polychem Handelsgesellschaft M.B.H. on December 23, 2021. Post completion, 65 employees of Polychem Handelsgesellschaft M.B.H. will become part of IMCD N.V. The transaction is subject to customary regulatory review and the closing is expected to take place during the first quarter of 2022. In 2020, Polychem Handelsgesellschaft M.B.H. generated a revenue of approximately €25 million. Reported Earnings • Aug 05
First half 2021 earnings released: EPS €1.85 (vs €1.22 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €1.69b (up 19% from 1H 2020). Net income: €105.4m (up 64% from 1H 2020). Profit margin: 6.2% (up from 4.5% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. 공시 • Jul 16
IMCD N.V. (ENXTAM:IMCD) entered into an agreement to acquire Materias Quimicas De Mexico, S.A. De C.V. IMCD N.V. (ENXTAM:IMCD) entered into an agreement to acquire Materias Quimicas De Mexico, S.A. De C.V. on July 16, 2021. The closing of the transaction is expected to take place in August 2021. Executive Departure • Jun 29
Independent Member of Supervisory Board Michel G. Plantevin has left the company On the 24th of June, Michel G. Plantevin's tenure as Independent Member of Supervisory Board ended after 10.3 years in the role. We don't have any record of a personal shareholding under Michel G.'s name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 25.42 years. Upcoming Dividend • Jun 17
Upcoming dividend of €1.02 per share Eligible shareholders must have bought the stock before 24 June 2021. Payment date: 28 June 2021. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (1.3%). 공시 • Jun 03
IMCD N.V. (ENXTAM:IMCD) acquired Shanghai Yuanhe Chemicals Co., Ltd. IMCD N.V. (ENXTAM:IMCD) acquired Shanghai Yuanhe Chemicals Co., Ltd on June 2, 2021. Yuanhe generated a revenue of €13.2 million The acquisition adds 20 employees to the IMCD China team.
IMCD N.V. (ENXTAM:IMCD) completed the acquisition of Shanghai Yuanhe Chemicals Co., Ltd on June 2, 2021. 공시 • May 19
IMCD N.V. (ENXTAM:IMCD) acquired Andes Chemical Corp. IMCD N.V. (ENXTAM:IMCD) acquired Andes Chemical Corp. on May 17, 2021. Andes Chemical generated revenue of $46 million in 2020. The acquisition of Andes Chemical adds 43 employees to IMCD’s Americas team, plus a CASE innovation laboratory located in Miami which provides product and formulatory support.
IMCD N.V. (ENXTAM:IMCD) completed the acquisition of Andes Chemical Corp. on May 17, 2021. Is New 90 Day High Low • Mar 11
New 90-day high: €112 The company is up 8.0% from its price of €104 on 10 December 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Trade Distributors industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €60.65 per share. Reported Earnings • Mar 01
Full year 2020 earnings released: EPS €2.25 (vs €2.06 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €2.79b (up 3.1% from FY 2019). Net income: €120.9m (up 12% from FY 2019). Profit margin: 4.3% (up from 4.0% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Mar 01
Revenue beats expectations Revenue exceeded analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 9.6%, compared to a 4.6% growth forecast for the Trade Distributors industry in Germany. 공시 • Feb 26
IMCD N.V. Announces Management Changes, Effective 26 February 2021 IMCD N.V. announced that Janus Smalbraak has been appointed chair of the Supervisory Board as per 26 February 2021. He takes over from Michel Plantevin, who is retiring from the Supervisory Board at the end of his current (fourth and final) term. Is New 90 Day High Low • Jan 23
New 90-day high: €110 The company is up 6.0% from its price of €105 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Trade Distributors industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €69.85 per share. 공시 • Dec 05
IMCD N.V. (ENXTAM:IMCD) acquired Millikan S.A. de C.V. and Banner Química S.A. de C.V. IMCD N.V. (ENXTAM:IMCD) acquired Millikan S.A. de C.V. and Banner Química S.A. de C.V. on December 4, 2020. Millikan and Banner Química collectively generated a revenue of $15 million in 2019 and add 60 employees to the IMCD Mexico team.
IMCD N.V. (ENXTAM:IMCD) completed the acquisition of Millikan S.A. de C.V. and Banner Química S.A. de C.V. on December 4, 2020. 공시 • Nov 27
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire the personal care business of Ejder Kimya Ilaç Danismanlik Sanayi ve Ticaret A.S. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire the personal care business of Ejder Kimya Ilaç Danismanlik Sanayi ve Ticaret A.S. on November 26, 2020. In 2019, the personal care business reported a total revenue of € 4.7 million. The closing of the transaction is subject to customary closing conditions and regulatory approval and is expected to close in early January 2021. 공시 • Nov 06
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Pharmaceutical Business of Peak International Products B.V. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Pharmaceutical Business of Peak International Products B.V. on November 5, 2020. In 2019, Pharmaceutical Business reported total revenues of approximately €5.8 million. Pharmaceutical Business will be integrated into IMCD Business Group Pharmaceuticals. Is New 90 Day High Low • Nov 05
New 90-day high: €108 The company is up 20% from its price of €89.68 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Trade Distributors industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €72.66 per share. Is New 90 Day High Low • Oct 19
New 90-day high: €106 The company is up 18% from its price of €89.20 on 21 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Trade Distributors industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €78.12 per share. 공시 • Sep 18
IMCD N.V. (ENXTAM:IMCD) acquired Oy Kokko-Fiber Ab. IMCD N.V. (ENXTAM:IMCD) acquired Oy Kokko-Fiber Ab on September 18, 2020. Oy Kokko-Fiber Ab reported revenue of €9 million as of December 31, 2019. Oy Kokko-Fiber Ab will continue with its present management and staff.
IMCD N.V. (ENXTAM:IMCD) completed the acquisition of Oy Kokko-Fiber Ab on September 18, 2020. 공시 • Sep 01
IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Siyeza Fine Chem Propriety Limited. IMCD N.V. (ENXTAM:IMCD) signed an agreement to acquire Siyeza Fine Chem Propriety Limited on September 1, 2020. Siyeza Fine Chem Propriety Limited generated a revenue of €11.7 million in 2019The company will continue with its present management and staff. The transaction is subject to approval by regulatory board/committee. The closing of the transaction is expected in December 2020. 공시 • Aug 22
IMCD N.V. (ENXTAM:IMCD) completed the acquisition of pharmaceutical business of Develing International Trade (Shanghai) Co. Ltd. IMCD N.V. (ENXTAM:IMCD) entered into agreement to acquire the pharmaceutical business of Develing International Trade (Shanghai) Co. Ltd. on May 15, 2020. The business reports sales of €10 million will be integrated into IMCD China’s business unit Pharma and will be synergistic with IMCD’s existing product range. The deal is subject to fulfillment of conditions.
IMCD N.V. (ENXTAM:IMCD) completed the acquisition of pharmaceutical business of Develing International Trade (Shanghai) Co. Ltd. on August 18, 2020. 공시 • Aug 20
IMCD N.V. (ENXTAM:IMCD) acquired VitaQualy Comercio de Ingredientes LTDA. IMCD N.V. (ENXTAM:IMCD) acquired VitaQualy Comercio de Ingredientes LTDA on August 19, 2020. VitaQualy Comercio de Ingredientes LTDA will be fully integrated into IMCD N.V. in 2021.
IMCD N.V. (ENXTAM:IMCD) completed the acquisition of VitaQualy Comercio de Ingredientes LTDA on August 19, 2020.